In a report released yesterday, Kumaraguru Raja from CIM Securities maintained a Buy rating on VBI Vaccines (NASDAQ: VBIV), with a price target of $10. The company’s shares closed yesterday at $1.92, close to its 52-week low of $1.68.
According to TipRanks.com, Raja is a 1-star analyst with an average return of -2.1% and a 54.5% success rate. Raja covers the Healthcare sector, focusing on stocks such as Corbus Pharmaceuticals, Acer Therapeutics Inc, and Tonix Pharma.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for VBI Vaccines with a $12 average price target.
See today’s analyst top recommended stocks >>
Based on VBI Vaccines’ latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $16.73 million. In comparison, last year the company had a GAAP net loss of $9.01 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
VBI Vaccines, Inc. is a biopharmaceutical company, which develops vaccines for infectious disease and immuno-oncology. Its pipeline includes Sci-B-Vac, CMV Vaccine, GBM Immunotherapy, MB Immunotherapy, and Zika Vaccine. The company was founded on July 9, 2015 is headquartered in Cambridge, MA.
